Mouthwashes with Plain Water Prevent Oral Mucositis Secondary to Hematopoietic Stem Cell Transplantation in Hematological Cancer Patients: A Retrospective Study

Xinwen Du  
Sichuan University West China Hospital Department of Hematology/West China School of Nursing

Chuanli Zhang  
Sichuan University West China Hospital Department of Hematology/West China School of Nursing

Fengjiao Chen  
Sichuan University West China Hospital Department of Hematology/West China School of Nursing

Yamei Leng  
Sichuan University West China Hospital Department of Hematology/West China School of Nursing

Yuhuan Zheng (zhengyuhuan@scu.edu.cn)  
Sichuan University West China Hospital  
https://orcid.org/0000-0002-5855-4343

Keywords: Oral mucositis, hematopoietic stem cell transplantation, plain water mouthwash

Posted Date: November 19th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-879575/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background Oral mucositis (OM) is a common adverse effect in hematological cancer patients who have received hematopoietic stem cell transplantation (HSCT). In this study, we compared mouthwash with nystatin, aloe vera or plain water in OM prevention.

Design A retrospective chart review was conducted in participants. The incidence, severity and duration of OM, duration of oral pain, and the use of antalgesics were recorded.

Setting/participants Hematological cancer patients who had received HSCT from January 2014 to December 2020 in West China Hospital were included in this study.

Results A total of 150 patients were included in our retrospective analysis. The nystatin group had the highest incidence (100.0%) of OM, followed by the aloe vera group (44.8%), the plain water group had the lowest incidence of OM (20.0%), and the nystatin group had the highest severity and the longest duration of oral mucositis. The incidence, severity and duration of pain in the nystatin group were significantly higher than the aloe vera group and plain water group, and the use of analgesic drugs in the nystatin group was also significantly higher than the other two groups (P<0.05).

Conclusions In our hospital setting, plain water mouthwash achieves great effect in OM prevention in hematological cancer patients who have received HSCT.

Introduction

Hematopoietic stem cell transplantation (HSCT) has been widely used in treatment of different hematological cancers, such as lymphoma, leukemia and multiple myeloma[1]. As estimated, approximately 80,000 patients receive HSCT annually in the world, and the survival rate after HSCT exceeds 80% [2]. In general, high-dose chemotherapy or radiotherapy in conditioning regimens before HSCT is necessary to suppress the immune system, destroy any residual tumor cells and make room in the bone marrow for implanted stem cells[3]. However, patients will suffer from autoimmune dysfunction, systemic or local skin and mucosal damage due to the systemic toxicity and side effects resulted from high-dose chemotherapy or radiotherapy [4, 5]. Pre-HSCT chemotherapy and radiotherapy can inhibit epithelial cell renewal and destroy the normal ecological environment of the oral cavity, therefore result in oral mucositis (OM). A previous study reported that approximately 80% patients had developed OM secondary to HSCT [6]. The symptoms of OM include pain, erythema, oedema, haemorrhage and ulcerations, all of which affect the patients’ quality of life. In some rare cases, severe OM may occur and interfere post-HSCT anti-tumor therapy. Therefore, it is necessary to implement effective preventive managements to avoid OM in patients undergoing HSCT.

According to clinical practice guidelines of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/ International Society for Oral Oncology (MASCC/ISOO) and European Society for Medical Oncology (ESMO)[7, 8], basic oral care (BOC) is recommended for cancer patients to prevent OM after all therapeutic modalities. Rinsing mouth is a key step of BOC. However, the choice of agents for mouthwash is not standardized, probably because of inadequate and/or conflicting evidences [7, 9]. In this study, we retrospectively reviewed the methods and agents used for mouthwash in patients who underwent HSCT, and identified the effect way to prevent post-HSCT OM.
Materials And Methods

Patients and study design

In this retrospective study, we reviewed medical charts of patients hospitalized in Department of Hematology, West China Hospital, Sichuan University, CHINA, from January 2014 to December 2020. The patients’ demographic and clinical information were retrieved from the hospital medical information system. This retrospective study was approved by the Medical Ethics Committee, West China Hospital, Sichuan University (approval #: 2021/888). The inclusion criteria included: 1) patients were diagnosed with leukemia, myelodysplastic syndrome, multiple myeloma, or lymphoma according National Comprehensive Cancer Network (NCCN) clinical diagnosis and treatment guidelines; 2) the patients were ≥ 14 years old; 3) the patients were underwent HSCT; 4) the patients volunteered to participate in this study; 5) the patients received single agents mouthwash. The exclusion criteria included: 1) patients had incomplete data; or 2) patients had OM before HSCT. All patients who received HSCT in our hospital were asked to do mouthwash to prevent OM. The patient could choose from three different rinse solutions, nystatin (a polyene anti-fungal agent), aloe vera (a perennial plant belongs to the Liliaceae family) or plain water. In most cases, if not all of them, the patients stayed with one rinse solution throughout the post-HSCT recovery.

Oral mucositis measurement

The occurrence and severity of OM in patients were diagnosed by the World Health Organization oral toxicity scale[10]. In brief, Grade 0 means no mucositis; Grade I means erythema and soreness may include buccal scalloping with or without erythema; Grade II means erythema is obvious, the pain is aggravated, the ulcers are scattered, and require a semi-liquid diet; Grade III means the mucosal ulcer is more obvious than the Grade II, and only a liquid diet can be taken; Grade IV means severe pain, mucositis to the extent that alimentation is not possible, and food cannot be eaten. The symptom of oral pain was evaluated by Numerical Rating Scale (NRS) with a number from 0 to 10 to indicate the degree of pain, 0 means no pain, and 10 means the most painful [11]. Other related information, such as OM location and duration, was also recorded.

Statistic analysis

SPSS version 21.0 (Statistical Package for the Social Sciences; IBM Corp., Armonk, NY) was used for data analysis. Descriptive statistics were used to describe all study variables including demographic and clinical data. One-way analysis of variance or a nonparametric test (Kruskal-Wallis test) for continuous variables (age, BMI, duration of OM, severity and duration of pain), and the chi-square test for categorical variables (sex, education, marital status, employment, diagnosis, treatment, incidence, severity and location of OM, incidence of pain and use of analgesics) were employed to compare the differences among three groups.

Results

The sociodemographic and clinical characteristics of the participants

As described earlier in Materials and Methods section, a total of 150 patients who received HSCT from 2014 to 2020 in West China Hospital, were included in this study. The patients were categorized into 3 groups based on
the different ways of mouthwashes. Specifically, 47 patients used nycostin, 58 patients used aloe vera, and 45 used plain water. Mouthwash methods were summarized in Table 1. Demographic characteristics of patients were summarized in Table 2. There were no significant difference among three groups of patients except patients received plain water mouthwash had slightly higher of BMI than the other groups.

Table 1
Mouthwash methods

|                        | Nycostin Group                                                                 | Aloe Vera Group                                                                 | Plain Water Group                |
|------------------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------------|---------------------------------|
| **Frequency**          | Rinse mouth upon awakening, before sleeping and at least four times a day after brushing |                                                                                 |                                 |
Table 2
Comparison of sociodemographic and clinical characteristics among three groups (N = 150)

| Items                        | Nystatin Group (n = 47) | Aloe Vera Group (n = 58) | Plain Water Group (n = 45) | F/χ² | P  |
|------------------------------|-------------------------|--------------------------|---------------------------|------|----|
| Age                         | 35.64±12.24             | 35.50±12.34              | 40.89±14.56               | 2.641<sup>a</sup> | 0.075 |
| Gender                      |                         |                          |                           |      |    |
| Male                        | 28(59.6)                | 30(51.7)                 | 22(48.9)                  | 1.153<sup>b</sup> | 0.590 |
| Female                      | 19(40.4)                | 28(48.3)                 | 23(51.1)                  |      |    |
| Level of education          |                         |                          |                           |      |    |
| Middle school or below      | 13(27.7)                | 14(24.1)                 | 20(44.4)                  | 5.628<sup>b</sup> | 0.232 |
| High school                 | 10(21.3)                | 15(25.9)                 | 7(15.6)                   |      |    |
| Junior college or above     | 24(51.1)                | 29(50.0)                 | 18(40.0)                  |      |    |
| Marital status              |                         |                          |                           |      |    |
| Married                     | 39(83.0)                | 40(69.0)                 | 30(66.7)                  | 3.732<sup>b</sup> | 0.160 |
| Single/Divorced             | 8(17.0)                 | 18(31.0)                 | 15(33.3)                  |      |    |
| Employment status           |                         |                          |                           |      |    |
| Employed                    | 32(68.1)                | 38(65.5)                 | 26(57.8)                  | 3.723<sup>b</sup> | 0.453 |
| Retired                     | 3(6.4)                  | 1(1.7)                   | 4(8.9)                    |      |    |
| Unemployed                  | 12(25.5)                | 19(32.8)                 | 15(33.3)                  |      |    |
| Diagnosis                   |                         |                          |                           |      |    |
| Leukemia                    | 34(72.3)                | 34(58.6)                 | 26(57.8)                  | -5.356<sup>b</sup> | 0.503 |
| MDS*                        | 2(4.3)                  | 3(5.2)                   | 2(4.4)                    |      |    |
| MM*                         | 2(4.3)                  | 8(13.8)                  | 8(17.8)                   |      |    |
| Lymphoma                    | 9(19.1)                 | 13(22.4)                 | 9(20.0)                   |      |    |
| BMI*                        | 20.67±1.41              | 21.19±2.01               | 22.19±2.83                | 6.045<sup>a</sup> | 0.003 |
| Treatment                   |                         |                          |                           |      |    |
| ASCT*                       | 16(34.0)                | 24(41.4)                 | 17(37.8)                  | 0.595<sup>b</sup> | 0.775 |
| OSCT*                       | 31(66.0)                | 34(58.6)                 | 28(62.2)                  |      |    |

<sup>a</sup> F value; <sup>b</sup> χ²; MDS* (Myelodysplastic syndromes); MM* (Multiple myeloma); BMI* (Body Mass Index); ASCT* (Allogeneic stem cell transplantation); OSCT* (Autologous stem cell transplantation).
The preventive effect of three mouthwash on OM

There were statistically significant differences in the incidence, severity and duration of OM among the three groups ($p < 0.05$) (Table 3). The nystatin group had the highest incidence (100.0%) of OM, followed by the aloe vera group (44.8%), and the plain water group had the lowest incidence (20.0%) of OM. Furthermore, the nystatin group had the highest severity and the longest duration of OM. The OM of the participants occurred in multiple locations. There were significant differences in the incidence of OM in the lingual surface, upper jaw, lip, throat and other parts among three groups ($p < 0.05$).
Table 3
Comparison of OM occurrence among three groups (N = 150)

| Items         | Nystatin Group (n = 47) | Aloe Vera Group (n = 58) | Plain Water Group (n = 45) | χ²/Z  | P     | Multiple-Comparison |
|---------------|-------------------------|--------------------------|-----------------------------|-------|-------|---------------------|
| Incidence     | 47(100.0)               | 26(44.8)                 | 9(20.0)                     | 77.108a | < 0.001* | G1 > G2*            |
|               |                         |                          |                             |       |       | G1 > G3*            |
|               |                         |                          |                             |       |       | G2 > G3*            |
| Severity      | 0(0.0)                  | 32(55.2)                 | 36(80.0)                    | 96.726a | < 0.001* | G1 > G2*            |
| Grade 0       | 18(38.3)                | 24(41.4)                 | 4(8.9)                      |       |       | G1 > G3*            |
| Grade I       | 18(38.3)                | 2(3.4)                   | 4(8.9)                      |       |       | G1 > G3*            |
| Grade II      | 7(14.9)                 | 0(0.0)                   | 1(2.2)                      |       |       |                    |
| Grade III     | 4(8.5)                  | 0(0.0)                   | 0(0.0)                      |       |       |                    |
| Duration      | 13.00(6.00,18.00)       | 0.00(0.00,7.25)          | 0.00(0.00,0.00)             | 62.978b | < 0.001* | G1 > G2*            |
|               |                         |                          |                             |       |       | G1 > G3*            |
| Position      |                         |                          |                             |       |       |                    |
| Lingual surface | 24(51.1)              | 14(24.1)                 | 3(6.7)                      | 23.739a | < 0.001* | G1 > G2*            |
|               |                         |                          |                             |       |       | G1 > G3*            |
| Upper jaw     | 17(36.2)                | 3(5.2)                   | 0(0.0)                      | 29.084a | < 0.001* | G1 > G2*            |
|               |                         |                          |                             |       |       | G1 > G3*            |
| Lips          | 21(44.7)                | 0(0.0)                   | 3(6.7)                      | 41.241a | < 0.001* | G1 > G2*            |
|               |                         |                          |                             |       |       | G1 > G3*            |
| Checks        | 8(17.0)                 | 4(6.9)                   | 2(4.4)                      | 4.376a  | 0.116   |                    |
| Throat        | 36(76.6)                | 1(1.7)                   | 4(8.9)                      | 84.472a | < 0.001* | G1 > G2*            |
|               |                         |                          |                             |       |       | G1 > G3*            |
| Gingiva       | 2(4.3)                  | 0(0.0)                   | 0(0.0)                      | 2.951a  | 0.185   |                    |
| Apex linguae  | 8(17.0)                 | 2(3.4)                   | 4(8.9)                      | 5.444a  | 0.055   |                    |

aχ², b Z value; * P < 0.05.

The oral pain among three groups
There were statistically significant differences of oral pain among three groups for the incidence, severity, and duration ($p < 0.05$) (Table 4). Nystatin group had the most severe oral pain with the incidence (93.6%), severity [3.00 (2.00, 4.00)] and duration [8.00 (3.00, 13.00)]. More nystatin group of patients had to use analgesic drugs than the other two groups of patients ($p < 0.05$) (Table 4).

### Table 4: Comparison of oral pain among three groups (N=150)

| Items       | Nystatin Group (n=47) | Aloe Vera Group (n=38) | Plain Water Group (n=45) | $\chi^2/Z$ | P     | Multiple-Comparison |
|-------------|------------------------|------------------------|--------------------------|------------|-------|---------------------|
| Incidence   | 44 (93.6)              | 36 (62.1)              | 26 (57.8)                | 20.056*    | <0.001* | G1>G2*              |
|             | [M (P25, P75) / n (%) ] | [M (P25, P75) / n (%) ] | [M (P25, P75) / n (%) ] |            |       |                     |
| Severity    | 3.00 (2.00, 4.00)      | 2.00 (0.00, 2.00)      | 2.00 (0.00, 3.00)        | 36.673*    | <0.001* | G1>G2*              |
| Duration    | 8.00 (3.00, 13.00)     | 0.50 (0.00, 5.00)      | 2.00 (0.00, 4.00)        | 24.283*    | <0.001* | G1>G2*              |
| Use of analgesics | 28 (59.6)          | 34 (91.1)              | 42 (93.3)                | 22.748*    | <0.001* | G1>G2*              |
| No          | 19 (40.4)              | 4 (6.9)                | 3 (6.7)                  |            |       |                     |
| Yes         |                       |                       |                         |            |       | G1>G3*              |

* $\chi^2$, $Z$ value, $* P<0.05$.

**Discussion**

Basic oral care is recommended for cancer patients to prevent OM caused by anti-tumor therapies [7, 8, 12]. In this study, we retrospectively review three methods of mouthwashes, nystatin, aloe vera, or plain water, in OM prevention in patients treated with HSCT. Our result suggested that plain water mouthwash could efficiently prevent OM occurrence in patients secondary to HSCT, and reduce the OM severity. Rinse mouth with plain water is easy, costless and well-tolerated, all of which may promote patient’s adherence to routine mouth care. Plain water rinse also reduces bacterial load in oral cavity and provide comfort. The mechanism of plain water rinse in OM prevention is still not fully demonstrated. One previous study suggested that plain water mouth rinse might promote oral cleanliness, therefore reduce oral infection [13]. Roopashri’s study showed that distilled water and other mouthwashes, such as benzydamine hydrochloride, chlorhexidine, and povidone iodine, had the same preventive effect on oral mucositis in cancer patients [14].

Compared with water, nystatin mouthwash could hardly prevent OM in our study. Nystatin belongs to polyeone anti-fungal agent[15]. Oral candidiasis is the most common opportunistic fungal infection of oral mucosa, and nystatin is considered as the first-line agent to treat oral candidiasis[16]. In Cidon’ study, nystatin mouthwash showed effective in oral candidiasis prevention [17]. However, another study also suggested that nystatin mouthwash, either alone or in combination with chlorhexidine, could not prevent OM in cancer patients [18]. Furthermore, an adverse effect of nystatin mouthwash was taste of the agent. Epstein et al.[15] found that the taste of nystatin during mouthwash might cause patient nausea and vomiting, thus decreasing the therapeutic compliance.
Aloe vera is a perennial plant which has ingredient of hydroxyanthraquinone derivatives that shows active in sterilizing, inflammation relieving, toxins breaking down, pain alleviating, wound healing and immune promoting[19, 20]. According to our result, aloe vera mouthwash showed effective in OM prevention. There were no severe OM (grade III or above) occurred in aloe vera group. Most patients with OM in this group healed within a week. Literature search returned controversial findings of aloe vera in OM prevention. A previous study showed that aloe vera had healing activity to different mucocutaneous problems[21]. While a meta-analysis found aloe vera mouthwash showed no superior effect on OM prevention, compared with other natural products, such as honey, chlorhexidine and curcumin. Further studies might be required to address the function of aloe vera in OM prevention.

The latest ESMO clinical practice guideline does not recommend any specific types of mouthwash in OM prevention, probably because of inadequate and/or conflicting clinical evidences[7]. The results of this study suggested that under the current medical conditions, hematological cancer patients who underwent HSCT could gain a benefit from plain water mouthwash in OM prevention.

**Conclusion**

We compared three different ways of mouthwashes, nystatin, aloe vera, and plain water, in preventing OM in hematological cancer patients secondary to HSCT. Plain water mouthwash effectively prevented occurrence and severity of OM in the patients.

**Declarations**

**Authors' contributions:** Conceptualization: all authors; Methodology: Chuanli Zhang, Fengjiao Chen, Xinwen Du; Formal analysis and investigation: Chuanli Zhang, Xinwen Du; Writing - original draft preparation: Xinwen Du; Writing - review and editing: Chuanli Zhang, Fengjiao chen, Yuhuan Zheng.

**Funding:** This study was supported by grants to Y.Z. from the National Science Foundation of China (No. 81870157 and No. 82070219), and the Sichuan University Faculty Start Fund.

**Conflicts of interest/Competing interests:** The authors declare no conflict of interest.

**Availability of data and material:** Data available on request from the authors.

**Code availability:** Not applicable.

**Ethics approval:** This retrospective study was approved by the Medical Ethics Committee®West China Hospital, Sichuan University (2021/888).

**Consent to participate:** Not applicable.

**Consent for publication:** Not applicable.

**References**
1. Thomas ED et al (1971) Allogeneic Marrow Grafting for Hematologic Malignancy Using HL-A Matched Donor-Recipient Sibling Pairs. Blood 38(3):267–287

2. Transplantation, t.W.N.f.B.a.M., <Global Transplant Activity Data.pdf>. 2020.

3. Copelan, EA.J.N.E.JM (2006) Hematopoietic stem-cell transplantation 354(17):1813–1826

4. Pinana JL et al (2014) Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. Ann Hematol 93(2):299–307

5. Srinivasan A et al (2014) Early infections after autologous hematopoietic stem cell transplantation in children and adolescents: the St. Jude experience. Transpl Infect Dis 16(1):90–97

6. Vera-Llonch M et al (2007) Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer 15(5):491–496

7. Peterson DE et al (2015) Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol 26 Suppl 5:v139–51

8. Elad S et al (2020) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 126(19):4423–4431

9. Hong CHL et al (2019) Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer 27(10):3949–3967

10. Organization WHJ.W.o.p., WHO Handbook for Reporting Results of Cancer Treatment. (1979) 48: p. 22–28

11. Ferrera-Valente MA, Pais-Ribeiro JL, Jensen MP (2011) Validity of four pain intensity rating scales Pain 152(10):2399–2404

12. Lalla RV et al (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120(10):1453–1461

13. McGuire DB et al (2013) Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 21(11):3165–3177

14. Roopashri G, Jayanthi K, Guruprasad R (2011) Efficacy of benzydamine hydrochloride, chlorhexidine, and povidone iodine in the treatment of oral mucositis among patients undergoing radiotherapy in head and neck malignancies: A drug trail. Contemp Clin Dent 2(1):8–12

15. Epstein JB et al., Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. 1992. 73(6): p. 682–9

16. da Silva RA et al (2020) Antifungal activity of Punicalagin-nystatin combinations against Candida albicans. Oral Dis 26(8):1810–1819

17. Cidon EU (2018) Chemotherapy induced oral mucositis: prevention is possible. Chin Clin Oncol 7(1):6

18. Saunders DP et al (2013) Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer 21(11):3191–3207

19. El-Gammal A et al (2018) Is There a Place for Local Natural Treatment of Psoriasis? Open Access Maced J Med Sci 6(5):839–842

20. Radha MH, Laxmipriya NP (2015) Evaluation of biological properties and clinical effectiveness of Aloe vera: A systematic review. J Tradit Complement Med 5(1):21–26

21. Metin ZG, Helvaci A, MG.J.J.o.AN Eren, Effects of Aloe vera in adults with mucocutaneous problems: A systematic review and meta-analysis. 2020